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Introduction: Plasmin is a trypsin like serine protease that can catalyze the 
hydrolytic cleavage of peptide bonds at the COOH sides of arginines and lysines in 
extracellular matrix (ECM) components including fibrin, laminin and fibronectin. 
Microplasminogen (µPlg) is the COOH-terminal portion of plasminogen from 531 to 
791, and has molecular weight of about 30kDa. µPlg consists of the catalytic domain 
of plasminogen and can be converted by many plasminogen activators, for example, 
streptokinase (SK) into microplasmin, which shares the same catalytic properties as 
human plasmin. µPlg can be used as a therapeutic agent in vitreoretinopathies and 
thrombotic diseases. 
Methods and Results: The purpose of this study was production and activation of 
recombinant µPlg. After codon optimization and synthesis of the µPlg gene, it was 
inserted into expression vector pPICZα and this plasmid was transformed into Pichia 
pastoris X-33 cells by electroporation. The selected positive transforments were 
transferred into YPM (yeast extract-peptone-methanol) medium and were induced 
by methanol. The recombinant protein (33kDa) was successfully secreted into the 
supernatant of the induction medium and was purified by Ni-sepharose column. The 
presence of the recombinant µPlg was confirmed by SDS-PAGE. The activation of 
µPlg by streptokinase was performed at a 1:1 molar ratio of streptokinase to µPlg at 
37°C for 2hr in Tris-HCl buffer, pH=7.8. Microplasminogen activity was measured 
by FDP (Fibrinogen Degradation Product) ELISA kit. In a blood sample the clot is 
broken down by plasmin. Some of These broken fibrin fragments are called d-
dimers. In general, D-dimer elevation indicates increased fibrin turnover. In this 
procedure, 30 μL of active enzyme was added. And the rate of D-dimers was 
measured at 380 μg/mL. While the natural amount of D-dimers in the blood is less 
than 40 μg/mL. 
Conclusions: The availability of microplasminogen with lower molecular weight 
can be a valuable pharmaceutical tool for treatment of thrombotic diseases and 
vitreoretinopathies because the isolation of autologous plasmin is an expensive and 
time-consuming process. In this study we managed to produce microplasminogen 
and successfully turn it into active microplasmin. However more effort is needed to 
increase the yields of Protein Production. 
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